Check for updates

OPEN ACCESS

EDITED BY Caterina Motta, Santa Lucia Foundation (IRCCS), Italy

REVIEWED BY Lindsay Marshall, Humane Society of the United States, United States Alessandro Martorana, University of Rome Tor Vergata, Italy

*CORRESPONDENCE Chunyong Chen, chenchy18@163.com

RECEIVED 03 November 2024 ACCEPTED 18 February 2025 PUBLISHED 13 March 2025

CITATION

Huang J, Long X and Chen C (2025) A realworld safety surveillance study of aducanumab through the FDA adverse event reporting system. *Front. Pharmacol.* 16:1522058. doi: 10.3389/fphar.2025.1522058

COPYRIGHT

© 2025 Huang, Long and Chen. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system

Jingjing Huang¹, Xiaohong Long² and Chunyong Chen^{2*}

¹Cardiac Intensive Care Unit, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China, ²Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Background: Alzheimer's disease poses a major public health challenge, with aducanumab's approval in 2021 as the first disease-modifying therapy raising important safety considerations. This study analyzed the Food Drug Administration Adverse Event Reporting System (FAERS) database to evaluate aducanumab's real-world safety profile and identify potential risk factors.

Methods: We conducted a comprehensive pharmacovigilance study using the FAERS database from January 2004 to June 2024, analyzing 510 aducanumabassociated reports from integrated databases containing over 18 million demographic records and 66 million drug records. Safety signals were evaluated using four complementary disproportionality methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Analyses were stratified by age and sex, with adverse events examined at both System Organ Class (SOC) and Preferred Term (PT) levels using SAS 9.4.

Results: Among 510 aducanumab-associated adverse event reports, predominantly from elderly patients (55.49% aged \geq 65 years), nervous system disorders were the most frequent (53.24%, n = 583). Amyloid related imaging abnormality-oedema/effusion (ARIA-E) and Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits (ARIA-H) emerged as the most significant safety signals (ROR: 53,538.3 and 38,187.9, respectively). Sex-stratified analysis showed comparable safety profiles between males and females, with ARIA-E related events, ARIA-H related events, maintaining strong signals across all age groups, particularly in patients \geq 75 years. The median time to adverse event onset was 146.0 days (IQR: 80.0–195.0). Temporal analysis revealed increasing signal strength for ARIA-related events from 2004–2024, with notable intensification during 2022–2023.

Conclusion: Our real-world analysis identified ARIA-related events as the primary safety concern for aducanumab, typically occurring within 146 days of treatment initiation, with comparable safety profiles across sex but heightened risks in

patients \geq 75 years. These findings support aducanumab's viability as a therapeutic option while emphasizing the critical importance of rigorous monitoring protocols, particularly for ARIA events during the first year of treatment.

KEYWORDS

food drug administration adverse event reporting system (FAERS), aducanumab, monoclonal antibody selectively target, real-world study, adverse events

1 Introduction

Alzheimer's disease (AD) represents an unprecedented healthcare challenge, with 6.9 million Americans over 65 currently diagnosed. This neurological burden is projected to increase substantially, as epidemiological models predict 13.8 million cases by 2060 (2024 Alzheimer's disease facts and figures, 2024). The devastating impact of AD extends beyond individual patients to families, healthcare systems, and societies, with global costs exceeding \$1 trillion annually (Skaria, 2022).

Despite decades of research, therapeutic options for AD have remained limited, with most available treatments providing only symptomatic relief rather than addressing the underlying pathology (Passeri et al., 2022; van der Flier et al., 2023). The amyloid hypothesis, which posits that β -amyloid (A β) accumulation is central to AD pathogenesis, has driven drug development efforts, though many candidates have failed in clinical trials (Selkoe and Hardy, 2016; Wu et al., 2022).

A breakthrough occurred in 2021 with the FDA's accelerated approval of aducanumab, the first disease-modifying therapy for AD (Tampi et al., 2021). This monoclonal antibody selectively targets and removes aggregated A β from the brain, representing a paradigm shift in AD treatment (Ali et al., 2022). The approval, while controversial, opened a new era in AD therapeutics and provided hope for millions of patients and their families.

However, the introduction of aducanumab into clinical practice has raised important safety considerations. The drug's mechanism of action, involving the clearance of cerebral amyloid, can lead to Amyloid-Related Imaging Abnormalities (ARIA) and other potential adverse effects (Agarwal et al., 2023; Hampel et al., 2023). As real-world use expands, comprehensive understanding of its safety profile becomes increasingly crucial for optimal patient care (Knopman et al., 2021).

Clinical trials of aducanumab provide crucial foundational safety data through rigorous scientific protocols, even with the natural constraints of sample size, study duration and population representation (Padala and Yarns, 2022). The progression from controlled trials to real-world practice represents a natural evolution in drug development, bringing distinct challenges in how we gather and analyze clinical data (Galvin et al., 2024). Real-world evidence is essential for understanding the full spectrum of adverse events and identifying potential risk factors across different patient populations. Recent initiatives, such as the International Collaboration for Alzheimer's Research and Evaluation in Alzheimer's Disease (ICARE AD) study, demonstrate the ongoing efforts to gather real-world safety data, despite the inherent complexities of post-marketing surveillance (Heidebrink and Paulson, 2024). Current pharmacovigilance studies, while establishing preliminary insights, need continuous updating as new data become available (Ameen et al., 2024). The evolution of safety monitoring systems, supported by advancing analytical capabilities (Silva et al., 2024), will gradually enhance our understanding of aducanumab's safety profile in routine clinical practice.

Our study addresses these knowledge gaps through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database, employing multiple complementary analytical approaches. While preclinical animal studies provided initial safety insights, their translational value has inherent limitations, highlighting the critical need for real-world safety assessments (Marshall et al., 2023). This investigation aims to characterize the safety profile of aducanumab in real-world settings, identify potential risk factors, and provide evidence-based guidance for clinical monitoring.

2 Materials and methods

2.1 Data source and study design

We analyzed adverse event reports from the FAERS database (January 2004-June 2024) after deduplication, integrating DEMO (n = 18, 278, 243), DRUG (n = 66, 418, 951), and REAC (n = 54, 336, 884) databases (Figure 1). The analysis focused on aducanumab as the primary suspect drug, examining both demographic patterns (n = 510 reports) and safety signals (n = 1,095 events) using four disproportionality methods of Proportional Reporting Ratio (PRR); Bayesian Confidence Propagation Neural Network (BCPNN) using Information Component (IC); Multi-item Gamma Poisson Shrinker (MGPS) using Empirical Bayes Geometric Mean (EBGM).

2.2 Signal detection analysis

For robust signal detection, we employed four complementary analytical methods (Supplementary Table S1): Reporting Odds Ratio (ROR) with 95% confidence intervals (CI), PRR, BCPNN, and MGPS. Each method provided unique statistical perspectives to ensure comprehensive safety signal evaluation. Each method provided unique statistical insights, confirming the robustness of our findings. The safety signal was considered significant when meeting all the following criteria: Case count \geq 3, Lower bound of ROR 95% CI > 1, PRR \geq 2 with $\chi^2 \geq$ 4, IC-2SD > 0, EBGM05 > 2.



2.3 Statistical analysis

Adverse events were analyzed at both System Organ Class (SOC) and Preferred Term (PT) levels. We performed stratified analyses by age (45–64, 65–74, and \geq 75 years) and sex. Time-to-onset analysis was conducted using cumulative distribution analysis. Descriptive statistics were presented as frequencies and percentages for categorical variables, and means (SD) or medians (IQR) for continuous variables. To detect potential safety signals, we employed multiple disproportionality analyses. These included the reporting odds ratio (ROR) with its 95% confidence interval, the proportional reporting ratio (PRR) assessed through chi-square testing, the Information Component (IC) evaluated with a two-standard-deviation threshold (IC-2SD), and the Empirical Bayes Geometric Mean (EBGM) with its 95% confidence interval. All analyses were performed using SAS 9.4 (Statistical Analysis System, version 9.4; SAS Institute Inc., Cary, NC, United States).

3 Results

3.1 Demographic and clinical characteristics

During the surveillance period from January 2004 to June 2024, 510 reports of adverse events associated with aducanumab were documented in the Food Drug Administration Adverse Event Reporting System (FAERS) database. Table 1 presents the demographic and clinical characteristics of these cases. The sex distribution was relatively balanced, with 49.80% (n = 254) being female and 44.51% (n = 227) male, while 5.69% (n = 29) of reports had unknown sex status. Age analysis revealed 32.55% (n = 166) aged 75 years or older, and 22.94% (n = 117) aged between 65 and 74 years. Temporal distribution highlighted a concentration of reports in recent years, particularly in 2022 (43.92%, n = 224) and 2023 (39.02%, n = 199). The primary sources of these reports were consumers (41.57%, n = 212), followed by

TABLE 1 Clinical and demographic overview of FAERS-reported aducanumab cases (2004–2024).

Characteristics	Case number, n (%)
Sex	
Female	254 (49.80)
Male	227 (44.51)
Unknown	29 (5.69)
Age	
<18	0 (0.00)
18-44	0 (0.00)
45-64	29 (5.69)
65-74	117 (22.94)
≥75	166 (32.55)
Unknown	198 (38.82)
Reporting year	
2016	18 (3.53)
2018	1 (0.20)
2019	2 (0.39)
2021	18 (3.53)
2022	224 (43.92)
2023	199 (39.02)
2024	48 (9.41)
Reported person	
Consumer	212 (41.57)
Not specified	3 (0.59)
Pharmacist	120 (23.53)
Physician	175 (34.31)
Reported Countries (Top Five)	
United States	473 (92.75)
Japan	10 (1.96)
Canada	5 (0.98)
France	4 (0.78)
Switzerland	4 (0.78)
AE severity	
Serious	258 (50.59)
Non-Serious	252 (49.41)
Outcome	
Life-threatening	8 (1.57)
Hospitalization - initial or prolonged	121 (23.73)
Disability	2 (0.39)
	(Continued in next column)

TABLE 1 (*Continued*) Clinical and demographic overview of FAERS-reported aducanumab cases (2004–2024).

Characteristics	Case number, n (%)
Death	29 (5.69)
Congenital anomaly	0 (0.00)
Required intervention to Prevent permanent Impairment/damage	2 (0.39)
Other	135 (26.47)
Time to onset of SG related AEs	
0-30 days	25 (4.90)
31-60 days	18 (3.53)
61–90 days	21 (4.12)
91-120 days	33 (6.47)
121-150 days	23 (4.51)
151-180 days	39 (7.65)
181-360 days	43 (8.43)
>360 days	15 (2.94)
Weight (Kg)	
N (Missing)	170 (340)
Mean (SD)	71.49 (16.36)
Median (Q1,Q3)	69.62 (60.80,80.30)
Min, Max	34.20,132.00

Abbreviations: AE, adverse event; CI, confidence interval; FAERS, FDA, adverse event reporting system; IQR, interquartile range; Max, Maximum; Min, Minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; SG, suspected group; USA, United States.

physicians (34.31%, n = 175) and pharmacists (23.53%, n = 120). Geographically, the reports were overwhelmingly from the United States (92.75%, n = 473), with Japan (1.96%, n = 10) and Canada (0.98%, n = 5) also contributing.

3.2 Adverse event distribution by system organ class

Analysis of adverse events by SOC revealed that nervous system disorders were predominant, accounting for 53.24% (n = 583) of all reported events (Figure 2). This was followed by injury, poisoning and procedural complications (7.67%, n = 84) and psychiatric disorders (7.58%, n = 83). General disorders and administration site conditions (6.85%, n = 75) and gastrointestinal disorders (3.56%, n = 39).

3.3 Disproportionality analysis at SOC level

As detailed in Table 2, disproportionality analysis identified 22 system organ classes (SOCs) of adverse events. Nervous



system disorders were the most frequently reported, comprising 352 cases with significant disproportionality (ROR of 10.82, PRR of 4.04), followed by injury, poisoning, and procedural complications (n = 63), and psychiatric disorders (n = 58). Psychiatric disorders and ear and labyrinth disorders, despite showing notable signals, did not reach statistical significance.

3.4 Specific adverse event signals and profile

 100). Other neurological events such as headache (n = 41) and cerebral hemorrhage (n = 27) also displayed strong signals. The distribution of individual adverse events (Figure 3) showed that ARIA-E was the most frequently reported event (12.88%, n = 141), followed by ARIA-H (9.13%, n = 100). Other significant neurological events included headache (3.74%, n = 41), confusional state (3.20%, n = 35), and cerebral hemorrhage (2.47%, n = 27). Cognitive-related events such as dementia Alzheimer's type (1.92%, n = 21) and cognitive disorder (1.55%, n = 17) were also prominently reported.

3.5 Temporal analysis of safety signals

The temporal analysis from 2004 to 2024 (Figure 4) demonstrated progressive accumulation of safety signals, particularly for ARIA-related events. The heat map visualization showed that ARIA-E and ARIA-H maintained consistently strong

SOC	Case number (n)	ROR (95% CI)	PRR (χ2)	IC (IC-2SD)	EBGM
Nervous system disorders	352	10.82 (8.97, 13.05)	4.04 (971.65)	2.01 (1.80)	4.04 (3.35)
Injury, poisoning and procedural complications	63	0.24 (0.19, 0.32)	0.34 (129.25)	-1.57 (-1.94)	0.34 (0.26)
Psychiatric disorders	58	1.13 (0.86, 1.48)	1.11 (0.73)	0.15 (-0.25)	1.11 (0.85)
General disorders and administration site conditions	53	0.39 (0.29, 0.52)	0.45 (45.09)	-1.14 (-1.54)	0.45 (0.34)
Gastrointestinal disorders	36	0.59 (0.42, 0.83)	0.62 (9.55)	-0.69 (-1.17)	0.62 (0.44)
Infections and infestations	28	0.31 (0.21, 0.46)	0.35 (39.51)	-1.51 (-2.03)	0.35 (0.24)
Investigations	20	0.66 (0.42, 1.04)	0.68 (3.27)	-0.56 (-1.19)	0.68 (0.43)
Cardiac disorders	20	0.59 (0.38, 0.93)	0.61 (5.38)	-0.72 (-1.33)	0.61 (0.39)
Musculoskeletal and connective tissue disorders	18	0.26 (0.16, 0.42)	0.29 (36.00)	-1.79 (-2.42)	0.29 (0.18)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	16	0.27 (0.16, 0.44)	0.29 (30.60)	-1.77 (-2.42)	0.29 (0.18)
Skin and subcutaneous tissue disorders	15	0.54 (0.33, 0.91)	0.56 (5.54)	-0.84 (-1.54)	0.56 (0.33)
Metabolism and nutrition disorders	15	0.28 (0.17, 0.47)	0.30 (26.61)	-1.72 (-2.39)	0.30 (0.18)
Vascular disorders	15	0.51 (0.30, 0.85)	0.52 (6.93)	-0.94 (-1.63)	0.52 (0.31)
Renal and urinary disorders	13	0.58 (0.34, 1.01)	0.60 (3.74)	-0.75 (-1.49)	0.60 (0.34)
Respiratory, thoracic and mediastinal disorders	10	0.19 (0.10, 0.35)	0.21 (34.04)	-2.28 (-3.06)	0.21 (0.11)
Eye disorders	9	0.43 (0.22, 0.84)	0.44 (6.57)	-1.18 (-2.02)	0.44 (0.23)
Ear and labyrinth disorders	7	1.22 (0.58, 2.58)	1.22 (0.28)	0.29 (-0.78)	1.22 (0.58)
Hepatobiliary disorders	3	0.14 (0.05, 0.45)	0.15 (15.26)	-2.75 (-3.86)	0.15 (0.05)
Blood and lymphatic system disorders	3	0.27 (0.09, 0.84)	0.28 (5.86)	-1.86 (-3.02)	0.28 (0.09)
Product issues	2	0.12 (0.03, 0.5)	0.13 (12.28)	-2.97 (-4.15)	0.13 (0.03)
ímmune system disorders	1	0.05 (0.01, 0.33)	0.05 (19.89)	-4.39 (-5.51)	0.05 (0.01)
Reproductive system and breast disorders	1	0.10 (0.01, 0.68)	0.10 (8.58)	-3.37 (-4.55)	0.10 (0.01)

TABLE 2 Disproportionality analysis of aducanumab-related adverse events by system organ class in FAERS.

Abbreviations: CI, confidence interval; EBGM, empirical bayes geometric mean; FAERS, FDA, adverse event reporting system; IC, information component; IC-2SD, information component minus two standard deviations; PRR, proportional reporting ratio; ROR, reporting odds ratio; SOC, system organ class.

positive signals (IC-2SD values of 6.83 and 6.30, respectively) throughout the surveillance period. The intensity of safety signals for neurological events showed notable increases in recent years, particularly during 2022–2023.

3.6 Stratified analysis

Sex-stratified analysis (Figure 5) revealed comparable safety profiles between males and females. In females, ARIA-E showed

TABLE 3 Multi-method disproportionality analysis of adverse events associated with aducanumab.

Preferred terms	Case number (n)	ROR (95% CI)	PRR (χ2)	IC(IC-2SD)	EBGM
ARIA-E	141	53538.3 (42177.8-67958.6)	46644.4 (3390009)	14.55 (6.83)	24044.0 (18942.0)
ARIA-H	100	38187.9 (29358.2-49673.2)	34700.5 (2041938)	14.32 (6.30)	20420.9 (15699.2)
Headache	41	3.77 (2.76-5.15)	3.66 (80.25)	1.87 (1.33)	3.66 (2.68)
Confusional state	35	12.42 (8.87-17.39)	12.05 (355.56)	3.59 (2.71)	12.05 (8.60)
Cerebral haemorrhage	27	42.86 (29.25-62.81)	41.83 (1075.76)	5.39 (3.54)	41.79 (28.52)
Fall	23	3.95 (2.61-5.97)	3.89 (49.58)	1.96 (1.20)	3.89 (2.57)
Superficial siderosis of CNS	22	35937.4 (20741.2-62267.2)	35215.4 (453124)	14.33 (3.80)	20598.1 (11888.2)
Dementia Alzheimer's type	21	128.36 (83.30-197.79)	125.91 (2596.15)	6.97 (3.61)	125.60 (81.51)
Seizure	20	6.56 (4.21-10.21)	6.46 (92.50)	2.69 (1.72)	6.46 (4.15)
Amyloid related imaging abnormalities	17	17487.2 (10039.7-30459.3)	17215.7 (217258)	13.64 (3.40)	12781.6 (7338.13)
Cognitive disorder	13	16.05 (9.29–27.73)	15.87 (181.19)	3.99 (2.17)	15.86 (9.18)
Brain oedema	13	59.01 (34.14-101.99)	58.32 (731.68)	5.86 (2.74)	58.25 (33.70)
Memory impairment	12	4.89 (2.77-8.63)	4.84 (36.68)	2.28 (1.10)	4.84 (2.74)
Atrial fibrillation	11	6.35 (3.50-11.50)	6.29 (49.06)	2.65 (1.29)	6.29 (3.47)
Subarachnoid haemorrhage	9	48.94 (25.39-94.34)	48.54 (418.73)	5.60 (2.16)	48.50 (25.16)
Head injury	8	14.43 (7.20-28.93)	14.33 (99.25)	3.84 (1.56)	14.33 (7.15)
Cerebral microhaemorrhage	7	1493.95 (702.77-3175.87)	1484.41 (10075.5)	10.49 (1.95)	1441.32 (678.01)
Transient ischaemic attack	5	8.02 (3.33-19.31)	7.99 (30.57)	3.00 (0.70)	7.99 (3.32)
Mental status changes	5	10.00 (4.15-24.07)	9.96 (40.30)	3.32 (0.82)	9.95 (4.13)
Aphasia	4	7.20 (2.70–19.22)	7.18 (21.28)	2.84 (0.39)	7.18 (2.69)
Disorientation	4	5.49 (2.06-14.66)	5.48 (14.64)	2.45 (0.24)	5.47 (2.05)
Subdural haematoma	3	11.44 (3.68–35.52)	11.41 (28.48)	3.51 (0.22)	11.40 (3.67)
Skin cancer	3	7.94 (2.56–24.67)	7.92 (18.15)	2.99 (0.09)	7.92 (2.55)
Posterior reversible encephalopathy syndrome	3	17.14 (5.52–53.22)	17.09 (45.44)	4.09 (0.32)	17.09 (5.50)
Cerebral infarction	3	6.76 (2.18–20.98)	6.74 (14.67)	2.75 (0.02)	6.74 (2.17)
Haemorrhage intracranial	3	10.71 (3.45-33.27)	10.69 (26.34)	3.42 (0.20)	10.68 (3.44)
Ischaemic stroke	3	9.32 (3.00-28.93)	9.29 (22.20)	3.22 (0.15)	9.29 (2.99)

Abbreviations: ARIA-E, Amyloid related imaging abnormality-oedema/effusion; ARIA-H, Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits; CI, confidence interval; CNS, central nervous system; EBGM, empirical bayes geometric mean; IC, information component; IC-2SD, information component minus two standard deviations; PRR, proportional reporting ratio; ROR, reporting odds ratio; SD, standard deviation.

the strongest signal (ROR: 52,161.7, 95% CI: 37,748.5–72,078.3), followed by ARIA-H (ROR: 38,672.6, 95% CI: 26,352.9–56,751.6). Males demonstrated similar patterns, with ARIA-E (ROR: 57,905.0, 95% CI: 39,334.0–85,244.2) and ARIA-H (ROR: 38,577.0, 95% CI: 26,204.3–56,791.8) being the most significant events. The age-stratified analysis (Figure 6) across three groups (45–64, 65–74, and \geq 75 years) showed that ARIA-related events maintained strong signals across all age groups, with the highest reporting odds in the \geq 75 years group. While cognitive disorders and neurological symptoms showed varying reporting frequencies among different age groups, with more reports from older patients, these findings reflect only reporting patterns rather than true incidence rates.

3.7 Time-to-onset analysis and comprehensive signal analysis

Time-to-onset analysis (Supplementary Figure S1) revealed a median time to event of 146.0 days (IQR: 80.0–195.0 days). The cumulative distribution showed a relatively steady increase in event occurrence over time, with most events occurring within the first 360 days of treatment initiation. The disproportionality analysis (Supplementary Figures S2) confirmed the robustness of safety signals, particularly for ARIA-related events. ARIA-E and ARIA-H showed the highest safety signals (IC-2SD: ALL = 6.83 and 6.30, respectively) (Figure 7). Other significant neurological events



Distribution of Adverse Events Associated with Aducanumab: Analysis of Case Numbers and Proportions. Frequency distribution of adverse events reported with aducanumab use. The x-axis shows the proportion of adverse events (%), and the y-axis lists individual adverse events. Each bar represents both the percentage and absolute number of cases (n). Abbreviations: COVID-19, Coronavirus disease 2019.

included superficial siderosis, cerebral hemorrhage, and confusional state (Figure 7).

4 Discussions

This comprehensive pharmacovigilance analysis of the Food Drug Administration Adverse Event Reporting System (FAERS) database has provided crucial insights into the safety profile of aducanumab in real-world clinical practice. As the first anti-amyloid β monoclonal antibody to receive FDA accelerated approval for Alzheimer's disease treatment (Cummings et al., 2021), understanding aducanumab's safety characteristics is paramount for optimal clinical implementation and patient care management.

The adverse events identified in our analysis demonstrate a clear correlation with the drug's mechanism of action. Aducanumab functions by selectively binding to and facilitating the clearance of amyloid β plaques in the mice brain, representing a significant advancement in disease-modifying therapies for Alzheimer's disease (Sevigny et al., 2016). The most prominent safety signals observed were Amyloid-Related Imaging Abnormalities (ARIA), specifically ARIA-E (edema) and Amyloid related imaging abnormalitymicrohaemorrhages and haemosiderin deposits (ARIA-H), which are mechanistically linked to the drug's effects on cerebral vasculature during amyloid protein clearance (Hampel et al., 2023; Doran and Sawyer, 2024). While these findings align with earlier clinical trial data, our study provides robust confirmation through larger-scale real-world evidence, offering clinicians valuable insights into the practical aspects of aducanumab administration.

A particularly noteworthy finding is the sex-neutral distribution of adverse events, suggesting that aducanumab's safety profile remains consistent across sex (Schneider, 2020; Choi et al., 2023). This observation contrasts with some previous studies of neurological therapeutics where sex-specific differences were



noted, potentially simplifying clinical decision-making processes. Higher adverse event rates were observed in patients \geq 75 years, consistent with the typical age distribution of dementia, necessitating closer monitoring in this population (Liew, 2020). The temporal analysis demonstrated that most adverse events manifested within 360 days of treatment initiation, with a median onset time of 146 days, establishing a critical monitoring window for clinical surveillance. This temporal pattern provides clinicians with a clear framework for patient monitoring and risk management strategies.

Our study's methodological strength lies in its novel application of four complementary disproportionality analysis methods, substantially enhancing the reliability of signal detection. This multi-modal analytical approach, unprecedented in previous aducanumab safety studies, provides a more comprehensive understanding of the drug's safety profile (Wang et al., 2024). Recent evidence suggests that aducanumab, as a diseasemodifying therapeutic agent, may offer enhanced efficacy when administered early in the disease course (Cummings et al., 2023; Ameen et al., 2024). This observation underscores the importance of carefully balancing therapeutic benefits against potential risks, particularly in early-stage Alzheimer's disease patients. Despite ongoing debates surrounding the amyloid hypothesis, compelling evidence from human genetics, biochemical analyses, histopathological examinations, and animal models strongly supports the pivotal role of β-amyloid in Alzheimer's disease pathogenesis (Musiek et al., 2021). Notably, extensive studies in

transgenic mouse models have demonstrated that aducanumab penetrates the blood-brain barrier, selectively binds to parenchymal AB, and substantially reduces both soluble and insoluble Aß levels in a dose-dependent manner (Sevigny et al., 2016). These preclinical findings align remarkably well with clinical observations, lending further credence to the therapeutic potential of this agent. Proteomic analyses have revealed significant modulation of several key proteins associated with mitochondrial function and metabolism in aducanumab-treated mice (Bastrup et al., 2021), offering fresh insights into the mechanism of action. Furthermore, three clinical studies have confirmed that aducanumab (3-10 mg/kg) significantly reduced amyloid plaque deposition as measured by PET imaging over a 1-year period compared to placebo (Day et al., 2022). This multilayered experimental evidence, particularly the marked effects observed in animal models, provides a robust scientific foundation for the clinical application of aducanumab.

The geographic distribution of adverse event reports, predominantly from the United States, reflects the drug's current approval status and usage patterns. This concentration of data from a single healthcare system provides consistency in reporting standards but also highlights the need for broader international safety surveillance as global adoption increases (Fang et al., 2014). Our large sample size and rigorous statistical methodology provide compelling safety signal evidence, despite the inherent limitations of FAERS data, including reporting bias and challenges in establishing causality.

Subgroup	PT (Preferred Terms)	N	ROR (95% CI)	Т					
Female	Superficial siderosis of central nervous system	8	64955.5(23471.9 - 179756)						
	Amyloid related imaging abnormality-oedema/effusion	72	52161.7(37748.5 - 72078.3)						-
	Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	45	38672.6(26352.9 - 56751.6)						
	Amyloid related imaging abnormalities	7	17265.9(7377.87 - 40406.4)						
	Cerebral microhaemorrhage	3	1624.46(513.91 - 5134.85)						
	Dementia Alzheimer's type	11	132.17(72.71 - 240.26)						-
	Brain oedema	7	72.49(34.38 - 152.86)			-		_	
	Cerebral haemorrhage	13	55.39(31.94 - 96.05)		-		0		
	Head injury	7	25.27(11.99 - 53.27)	-					
	Cognitive disorder	7	17.41(8.26 - 36.70)	-	_				
	Confusional state	19	14.21(8.99 - 22.46)						
	Transient ischaemic attack	3	9.98(3.21 - 31.03)	-	-				
	Seizure	11	8.11(4.46 - 14.73)						
	Breast cancer female	3	6.76(2.17 - 21.03)						
	Infusion related reaction	3	5.64(1.81 - 17.54)						
	Balance disorder	4	4.72(1.76 - 12.62)	-					
	Atrial fibrillation	3	4.27(1.37 - 13.28)	-					
	Fall	13	4.04(2.33 - 7.00)						
	Headache	25	3.88(2.60 - 5.79)						
	Gait disturbance	7	3.55(1.69 - 7.49)						
	Memory impairment	5	3.52(1.46 - 8.49)						
	Dehydration	4	3.39(1.27 - 9.07)						
Male	Amyloid related imaging abnormality-oedema/effusion	65	57905.0(39334.0 - 85244.2)						
	Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	53	38577.0(26204.3 - 56791.8)						
	Amyloid related imaging abnormalities	7	28780.3(10676.6 - 77581.4)						
	Superficial siderosis of central nervous system	14	25019.8(12650.0 - 49485.5)						
	Cerebral microhaemorrhage	4	1501.30(550.30 - 4095.76)						
	Dementia Alzheimer's type	8	94.66(47.04 - 190.51)		-	-			-
	Subarachnoid haemorrhage	7	68.53(32.48 - 144.59)			-		-	
	Brain oedema	5	38.13(15.80 - 92.06)	-					
	Cerebral haemorrhage	11	27.70(15.24 - 50.37)	-	-				
	Urinary incontinence	3	12.35(3.97 - 38.42)	-	_				
	Aphasia	3	11.48(3.69 - 35.71)	-	_				
	Confusional state	16	10.56(6.42 - 17.37)						
	Cognitive disorder	4	9.73(3.64 - 26.02)	-	-				
	Mental status changes	3	9.57(3.07 - 29.77)	-	-				
	Vertigo	3	7.84(2.52 - 24.39)	-	-				
	Lethargy	4	7.24(2.71 - 19.38)	-					
	Atrial fibrillation	7	6.43(3.05 - 13.57)	-					
	Memory impairment	6	6.00(2.68 - 13.42)	-					
	Urinary tract infection	5	5.70(2.36 - 13.76)	-					
	Seizure	9	5.65(2.92 - 10.93)						
	COVID-19	7	4.96(2.35 - 10.46)						
	Headache	15	4.00(2.39 - 6.68)						
	Fall	10	3.94(2.10 - 7.36)						
	General physical health deterioration	4	3.82(1.43 - 10.22)	-					

FIGURE 5

Sex-stratified analysis of adverse events associated with aducanumab: A reporting odds ratio analysis. The report of odds ratio (ROR) analysis of adverse events stratified by sex for aducanumab treatment. The forest plot displays preferred terms (PT) on the y-axis and corresponding ROR values with 95% confidence intervals (CI) on the x-axis. Notable signals include ARIA-E, ARIA-H, and other neurological events. The analysis demonstrates similar safety profiles between male and female subgroups, with ARIA-related events showing the highest reporting odds in both sexes. Abbreviations: ARIA, Amyloid related imaging abnormalities; ARIA-E, Amyloid related imaging abnormality-oedema/effusion; ARIA-H, Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits; CI, Confidence interval; COVID-19, Coronavirus disease 2019; PT, Preferred terms; ROR, Reporting odds ratio; UTI, Urinary tract infection.

Future research directions should focus on collecting long-term safety data and examining treatment experiences across diverse populations (Dickson et al., 2023). Particular attention should be paid to understanding the impact of genetic factors, such as APOE &4 carrier status, on safety outcomes (Raulin et al., 2022; Arafah et al., 2023; Tripathi et al., 2024). This could be implemented through routine APOE genotyping using established cost-effective methods, such as PCR-based techniques or mass spectrometry (Calero et al., 2018), which can be integrated into standard clinical workflows. While current insurance coverage for APOE testing varies among payers (Arias et al., 2021), emerging evidence supporting its role in treatment decision-making may justify broader coverage policies (Blasco and Roberts, 2023). Additionally, investigation of potential drug interactions and the effects of concurrent medications commonly prescribed to elderly patients warrants further study.

The safety signals identified through our analysis, particularly ARIA-related events, warrant careful consideration but should be viewed within the context of the drug's potential therapeutic benefits (Vaz et al., 2022). Our findings suggest that with appropriate patient selection and monitoring protocols, aducanumab maintains a manageable safety profile. This research provides valuable insights for risk management in clinical practice and supports the optimization of personalized treatment strategies.

In conclusion, while ARIA and other adverse events require vigilant monitoring, aducanumab emerges as a viable therapeutic

Patter N Description 1 Angel elade langing adormally usedmanifuluon 4 0.20120114.0010 2 Angel elade langing adormally usedmanifuluon 4 0.2012014.0010 3 Angel elade langing adormally usedmanifuluon 4 0.2012014.0010 4 Margel elade langing adormally usedmanifuluon 4 0.201201.0010 5 Margel elade langing adormally usedmanifuluon 4 0.20120.0010 6 Margel elade langing adormally usedmanifuluon 5 0.20120.0010 7 Carden adord 3 0.20120.0010 6 Margel elade langing adormally usedmanifuluon 5 0.20120.0010 7 Carden adord 3 0.20120.0010 7 Carden adord 3 0.20120.0010 7 Carden adord 3 0.20120.0010 7 Carden adord 1 0.20120.0010<					
Specifical idencis of cettar increase system1127272020000-000000000000000000000000000	Subgroup	PI(Preferred Terms)	N	ROR (95% CI)	
Ampiod related maging abnormality-microbasement happs and haemoschein daposts 4 1452,7061 (21-2005) Ampiod related maging abnormality-microbasement happs and haemoschein daposts 1 341410136 (21-2005) Steare 1 341410136 (21-2005) - Steare 1 341411413790 - Steare 3 1254407 (20-20) - Constrain Ablighters's type 3 14504 (31) - Steare 3 14504 (31) - - Constrain Ablighters's type 3 14504 (31) - - Constrain Ablighters's type 3 14504 (31) - - Constrain Ablighters's type 3 14504 (31) - - Relation 3 14504 (31) - - - Relation 3 320(47-40) - - - Condiscont data 3 320(47-40) - - - - Condiscont data 3 320(47-40) - - - - -	≥75	Amyloid related imaging abnormality-oedema/effusion	58	20767.7(14011.6 - 30781.5)	•
Anyloid related imaging abnormalities4444449(1084-1970)•Demonita Adviatione's type63/40(134-7790)•Setture10204(114-1790)•Corplote disorder51576(53-14.10)•Mertal status changes1120(40-3960)•Demonita Adviatione's type3140257-2459)•Corplote disorder140244-239)•Head right340257-2459)•Pacaderia140244-239)•Balance disorder140244-239)•Confusional state140244-239)•Balance disorder323(16-749)•Confusional state323(16-749)•Confusional state313(1624-639)•Confusional state323(1624-639)•Confusional state313(1624-639)•Confusional state313(1624-639)• <td></td> <td>Superficial siderosis of central nervous system</td> <td>11</td> <td>17277.7(7289.10 - 40954.1)</td> <td>•</td>		Superficial siderosis of central nervous system	11	17277.7(7289.10 - 40954.1)	•
Dementia Aldrinner's type431-41.14.793)4Seture102041.14.1789)4Cognitor disorder515768.27.437)4Rortal status changes3127487.7469.004Bedramic stroke31843.47.137)4Corebarh hermothage58.83.46.2139.004Corebarh hermothage64.82.44.327.004Corebard hermothage14.82.47.379.004Corebard hermothage34.32.14.47)4Corebard hermothage31.54.16.71.004Corebard hermothage31.54.16.71.004Corebard hermothage33.54.16.71.004Corebard hermothage33.54.16.71.004Corebard hermothage33.54.16.71.004Corebard hermothage33.54.16.71.004Corebard hermothage abnormally-sociematethusion31.54.16.71.004Corebard hermothage abnormally-sociematethusion10110.00.42.97.14.0004Corebard hermothage abnormally-sociematethusion11110.00.42.97.14.0004Corebard hermothage abnormally-sociematethusion131.54.14.67.004Feddache33.20.17.11.85.0044Corebard related imaging abnormally-sociematethusion141.24.14.07.004Feddache33.20.17.11.85.0044Corebard related imaging abnormally-sociematethusion131.63.14.64.004Feddache3 <td></td> <td>Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits</td> <td>45</td> <td>14562.7(9651.21 - 21973.5)</td> <td>•</td>		Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	45	14562.7(9651.21 - 21973.5)	•
Seture12040141-137804Cognitor disorder5135462-34304Kortal status changes3125467-36904Bidsenic strake318403-13304Constain hermothage518046-12304Constain hermothage14,0257-14904Headsche14,0257-14904Constain hat14,0257-14904Constainen state14,0214-13704Constainen state31,20147-14004Constainen state		Amyloid related imaging abnormalities	4	6154.58(1920.96 - 19718.7)	•
Cognitive disorder513/06/52.14.13)Merial status changes32.30(47.39.00)Icchamic statule34.802.47.24.91Cereical harmorhage34.802.47.24.91Meadarbi14.802.47.24.91Readarbi14.802.47.24.91Contraisonal state34.302.14.71)Dominal for diator34.302.14.71)Contraisonal state34.302.14.70)Contraisonal state33.20(17.409)Contraisonal state33.20(17.409)Contraisonal state33.20(17.409)Contraisonal state42.20(17.109)Contraisonal state11.1003.02673-440070Anyloid related imaging abnormality-molenablemonthages and haemosiderin deposes1Memory impairment33.20(17.409)Memory impairment33.20(17.409)Memory impairment33.20(17.409)Memory impairment33.20(17.409)Memory impairment33.20(17.409)Memory impairment33.20(17.118)Memory impairment33.20(17.118)Memory impairment33.20(17.118)Memory impairment33.20(17.118)Memory impairment33.20(17.118)Memory impairment state33.20(17.118)Memory impairment state33.20(17.118)Memory impairment state33.20(17.118)Memory impairment state33.20(17.118)Memory impairment state3 </td <td></td> <td>Dementia Alzheimer's type</td> <td>6</td> <td>34.74(15.48 - 77.93)</td> <td>+-</td>		Dementia Alzheimer's type	6	34.74(15.48 - 77.93)	+-
Interfal status changes3120(07-396)Behami status31803(13-383)Cerebral harmorhage51803(42-32)Head rigory31802(72-246)Head rigory31802(72-246)Readache6123(14-17)Cortoisonal date3123(14-17)Baharce disorder332(14-17)Cortoisonal date332(14-17)Cortoisonal date332(14-170)Gat disturbance432(14-170)Gat disturbance432(14-170)Gat disturbance422(10)(1351-4802)FeldAmyleid related imaging abnematily-optimatifusion1119180(2073-4807)FeldAmyleid related imaging abnematily-optimatifusion1322(10)(1351-4802)FeldAmyleid related imaging abnematily-optimatifusion1319180(2073-4807)FeldMemory impairment332(17-118)FeldFeldAmyleid related imaging abnematily-optimatifusion1419180(2073-4807)FeldFeldMemory impairment332(17-118)FeldFeldAmyleid related imaging abnematily-optimatifusion1419180(2073-4807)FeldFeldAmyleid related imaging abnematily-optimatifusion1419180(2073-4807)FeldFeldAmyleid related imaging abnematily-optimatifusion1419180(2073-4807)FeldFeldAmyleid related imaging abnematily-optimatifusion1419180(2073-4807)FeldFeldBain optimatily-microbare		Seizure	п	20.81(11.41 - 37.96)	•
Bichasmicistaske 3 H830.44-33.80) Cerebral haenonhage 5 4830.45-21.34 Maad hijvry 3 1802.27-2493 Maadache 8 4502.45-23.49 Confusional state 8 4502.45-23.49 Confusional state 8 4502.45-23.90 Balance disorder 3 4302.41-43.90 Antal familation 5 250(47-1.60) COVID-19 3 22019-1900 Gat disturbance 4 240(40-7.00) 414 Amyloid related imaging abnomality-ocdematifusion 13 91000253-1400.90 4144 Amyloid related imaging abnomality-ocdematifusion 13 91000257-1400.00 4144 Amyloid related imaging abnomality-ocdematifusion 11 91000257-1400.00 Memory impairment 3 1930347-0130.00 1 Memory impairment 3 1930347-0130.00 1 Suberficial state 3 1930347-0130.00 1 Memory impairment 3 1930347-0130.00 1 Subachricial dimaging abnormality-ocdematifusion 14 10518.00044-14591.00 1		Cognitive disorder	5	15.76(6.52 - 38.13)	-
Corebrait heamonhageSRR0.46-21.30Head Payry36002.57-2459)Headsche84.902.44-259Contacional state84.902.44-479Balance disorder34.202.14-471)Antait Borlation53.001.67-409COVID-1933.200.8-989COVID-1933.200.8-709COVID-1933.200.8-7094444Ampioid related imaging abnormality-ocdemateffusion1019.00287-48020Ampioid related imaging abnormality-ocdemateffusion1019.00287-48020Ampioid related imaging abnormality-increbaemonthages and haemosiderin deposits1119.00287-48020Ampioid related imaging abnormality-increbaemonthages and haemosiderin deposits1119.00287-48020Ampioid related imaging abnormality-increbaemonthages and haemosiderin deposits1119.00287-48020Feadsche33.2017-11.50•Kando de lated imaging abnormality-increbaemonthages and haemosiderin deposits1219.00281-0130Ampioid related imaging abnormality-increbaemonthages and haemosiderin deposits1319.00281-0130Ampioid related imaging abnormality-increbaemonthages and haemosiderin deposits1419.00281-0130Ampioid related imaging abnormality-increbaemonthages and haemosiderin deposits1319.00281-0130Ampioid related imaging abnormality-increbaemonthages and haemosiderin deposits1419.00281-0130Ampioid related imaging abnormality-increbaemonthages and haemosiderin deposits1319.00281-0130Ampioid related imagi		Mental status changes	3	12.70(4.07 - 39.60)	•
Head byury3\$10(257-245)Headsche10450(24-4.25)Contusional state14.32,11+.47)Balance disorder34.23,11+.70)Atrial forlation53.24(1.760)COUD-1933.20(1.048)Galt disturbance42.44(16e-7.60)Galt disturbance42.44(16e-7.60)47.40(16)5Arnyloid related imaging abnormality-increhaemorthages and haemosiderin deposits1110Ortusional state3111913(912479-1460)612Contusional state3131946(41-62.9)614Contusional state315Sperificial state316Contusional state3171913(912479-1460)618Contusional state319Headsche319Sperificial sidences in deriversis system119Sperificial sidences in deriversis system119Subarachnud haemonthages and haemosiderin deposits110Arnyloid related imaging abnormality-microhaemorthages and haemosiderin deposits119Subarachnud haemorthage4424(3237-1483)19Sperificial sidences in deriversis system3443(38-9-2976)10Dementia Atheimer's type3443(287-28-30)410Subarachnud haemorthage4424(2372)410Contusional state1194(41-45.91)4 <t< td=""><td></td><td>Ischaemic stroke</td><td>3</td><td>10.85(3.48 - 33.83)</td><td></td></t<>		Ischaemic stroke	3	10.85(3.48 - 33.83)	
Headache 10 4.90(241-92) Confusional state 2 4.332(241-71) Balance disorder 3 4.20(33-1137) Attraf förflason 3 3.20(17-1.80) COVID-19 3 3.20(10-9.90) Gat disturbance 4 2.84(10-7.00) 454 Amyloid related imaging abnormality-ocdemaleffusion 15 2.299(10033-4892) 454 Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits 11 1.999(59/79-44607) 454 Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits 11 1.999(59/79-44607) 454 Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits 11 1.999(59/79-44607) 454 Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits 11 1.999(59/79-44607) 454 Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits 13 1.951(94-613) 454 Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits 14 1.932(94-94-93) 454 Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits 23 1.942(94-193) 5 A		Cerebral haemorrhage	5	8.82(3.65 - 21.34)	-
Confusional state84.33(214.8.77)Balance disorder34.23(1.3.1.137)Atrial fortiation53.50(1.7.7.80)COVID-1933.20(10.7.90)Gat disturbance42.340(1.6.7.70)F5-64Amyloid related imaging abnormality-ordema/effusion152.259(107338.46922)F5-64Amyloid related imaging abnormality-ordema/effusion1319159(5.977-4.607)F5-64Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits1119159(5.977-4.607)F5-64Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits131954(6.46.219)F6-74Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits131954(6.46.219)F6-74Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits131954(6.46.219)F6-74Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits231952(8.04.8.4.519.2)F6-74Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits241952(8.04.8.4.519.2)F6-74Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits241952(8.04.9.4.519.2)F6-74Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits241952(8.04.9.4.519.2)F6-74Amyloid related imaging abnormality-microhaemonhages and haemosiderin deposits241952(8.04.9.4.519.2)F6Brain codoma49.440(20.7.9.23.3)F6Brain codoma <td< td=""><td></td><td>Head injury</td><td>3</td><td>8.01(2.57 - 24.95)</td><td></td></td<>		Head injury	3	8.01(2.57 - 24.95)	
Balance disorder 3 42(134-137) Atrial fibrilation 5 35(147-160) COVID-19 3 32(101-98) Gak disturbance 4 24(106-720) 4541 Amyloid related imaging abnormality-ocedemaleffusion 15 22991(0753-44592) 4544 Amyloid related imaging abnormality-microbaemonthages and haemosiderin deposits 11 1918(941-42.19) 4541 Amyloid related imaging abnormality-microbaemonthages and haemosiderin deposits 13 134(14-42.19) Memoy impairment 3 134(14-42.19) - Headache 3 1201(17-11.18) - Komfold related imaging abnormality-oedemaleffusion 4 27033(11208-14332) Image: State (11) 65-74 Amyloid related imaging abnormality-oedemaleffusion 3 1201(17-11.18) - 65-74 Amyloid related imaging abnormality-microbaemonthages and haemosiderin deposits 24 140248(1004-12.691.2) Image: State (11) 65-74 Amyloid related imaging abnormality-microbaemonthages and haemosiderin deposits 24 140248(1004-12.691.2) Image: State (11) 65-74 Amyloid related imaging abnormality-microbaemorthage (12) 1401432(10-12.1) <td></td> <td>Headache</td> <td>10</td> <td>4.95(2.64 - 9.29)</td> <td></td>		Headache	10	4.95(2.64 - 9.29)	
Atial fibrillation 5 35(147-160) COVID-19 3 32(147-160) Gat disturbance 4 28(168-760) 4544 Anyloid related imaging abnomality-oedemaleffusion 15 2289(10933-48902) 4544 Anyloid related imaging abnomality-incorbanemorhages and haemosiderin deposits 11 1918942073-448000 4544 Anyloid related imaging abnomality-incorbanemorhages and haemosiderin deposits 11 1918942073-448000 4544 Anyloid related imaging abnomality-oedemaleffusion 3 1946(41-42.19) 6574 Menory impairment 3 1945(41-618) 1680 Anyloid related imaging abnomality-oedemaleffusion 4 27033(11208-41532) Image: State 6574 Anyloid related imaging abnomality-oedemaleffusion 4 27033(11208-41532) Image: State 6574 Anyloid related imaging abnomalities 3 1935(1084-6183) Image: State 6574 Anyloid related imaging abnomalities 3 1932(1084-6183) Image: State 6574 Anyloid related imaging abnomalities 3 1932(1084-6183) Image: State 6574 Anyloid related im		Confusional state	8	4.32(2.14 - 8.71)	
COVID-19 3 3.20(.03-9.8) • Gat disturbance 4 2.54(1.06-7.00) • 45.41 Anyloid related imaging abnormality-ocdemarchfusion 15 2.2991(07535-48992) • 45.41 Anyloid related imaging abnormality-incrohaemorhages and haemosiderin deposits 11 19139(52.079-44699) • Memory impairment 3 18.54(6.14-0.29) • • Readsche 3 18.91(544-0.19) • • Superficial siderosis of central nervous system 7 17224.4654.80-41532.70 • F6-74 Anyloid related imaging abnormality-incrohaemorhages and haemosiderin deposits 28 16328.4(00454-2642.5) • 65-74 Anyloid related imaging abnormality-incrohaemorhages and haemosiderin deposits 28 16328.4(00454-2642.5) • 65-74 Anyloid related imaging abnormality-incrohaemorhages and haemosiderin deposits 28 16328.4(00454-2642.5) • 65-74 Anyloid related imaging abnormality-incrohaemorhages 3 6633.4(1845.0-2504.5) • 65-74 Anyloid related imaging abnormality-incrohaemorhages 3 6633.4(1845.0-2504.5) • 62 Benin		Balance disorder	3	4.23(1.36 - 13.17)	
Gat disturbance 4 2.84(1.06 - 7.60) 45-64 Anyloid related imaging abnormality-oedenule/flusion 15 2.8591(10738 - 48502) 45-64 Anyloid related imaging abnormality-incrobaemorhages and haemosiderin deposits 11 19139(82.097 - 44609) 4 Memory impairment 3 1954(641 - 62.19) - 4 Memory impairment 3 3.72(1.17 - 11.85) - 4 Anyloid related imaging abnormality-oedenule/flusion 48 2.7313.8(131208 - 41.532.2) Image: State 65-74 Anyloid related imaging abnormality-oedenule/flusion 48 2.7313.8(131208 - 41.532.2) Image: State 65-74 Anyloid related imaging abnormality-oedenule/flusion 48 2.7313.8(131208 - 41.532.2) Image: State 65-74 Anyloid related imaging abnormality-oedenule/flusion 48 2.7313.8(131208 - 41.532.2) Image: State 65-74 Anyloid related imaging abnormality-microhaemorhages and haemosiderin deposts 12 16328.4(104.0 - 2.597.9) Image: State 65-74 Anyloid related imaging abnormality-microhaemorhage 4 9.4(32.8(13.50 - 25.60) Image: State 65 Brain oederma 4 9.54(35.0 - 25.60) <t< td=""><td></td><td>Atrial fibrillation</td><td>5</td><td>3.56(1.47 - 8.60)</td><td></td></t<>		Atrial fibrillation	5	3.56(1.47 - 8.60)	
8-64 Amyloid related imaging abnormality-oodemaleffusion 15 22891(10753 - 48922) Imaging abnormality-microhaemorthages and haemosiderin deposits 11 191839(2497 - 44699) Imaging abnormality-microhaemorthages and haemosiderin deposits 11 191839(2497 - 44699) Imaging abnormality-microhaemorthages and haemosiderin deposits 11 191839(2497 - 44699) Imaging abnormality-microhaemorthages and haemosiderin deposits 13 1954(814 - 62 19) Imaging abnormality-microhaemorthages and haemosiderin deposits 3 327(117 - 118) Imaging abnormality-microhaemorthages and haemosiderin deposits 18 270338(81208 - 415332) Imaging abnormality-microhaemorthages and haemosiderin deposits 18 160288(00854 - 26425) Imaging abnormality-microhaemorthages and haemosiderin deposits 18 160288(00854 - 26425) Imaging abnormality-microhaemorthages and haemosiderin deposits 18 160288(00854 - 26425) Imaging abnormality-microhaemorthages and haemosiderin deposits 18 160288(00854 - 26425) Imaging abnormality-microhaemorthages Imaging abnormality-microhaemorthages 18 160288(00854 - 26425) Imaging abnormality-microhaemorthages Imaging abnormality-microhaemorthage Imaging abnormality-microhaemorthage Imaging abnormality-microhaemorthage Imaging abnormality-microhaemorthage Imaging abnormality-microhaemorthage Imaging abnormality-microhaemorthage Imaging abnormality-mi		COVID-19	3	3.20(1.03 - 9.98)	
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits11191839(32479 - 44699)Imaging abnormality-microhaemorrhages and haemosiderin deposits11191839(32479 - 44699)Imaging abnormality-microhaemorrhages and haemosiderin deposits131954(6.14 - 62.19)Imaging abnormality-microhaemorrhages66-74Amyloid related imaging abnormality-oedemaleffusion4827433.8(8120.8 - 41532.2)Imaging abnormality-microhaemorrhages and haemosiderin deposits2816528.8(1045.4 - 2642.5)Imaging abnormality-microhaemorrhagesImaging abnormality-microhaemorrhageImaging abnormal		Gait disturbance	4	2.84(1.06 - 7.60)	
Memory impairment: 3 1954(6.14-6.2.19) • Confusional state 3 189(1541-62.19) • Headache 3 3.72(1.17-11.85) • 65-74 Amyloid related imaging abnomalty-ocdema/effusion 48 27933.8(1920.8-1533.2) • Superficial siderosis of central nervous system 7 17228.4(648.03-4587.1) • Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 28 1693.88(1995.4-259.25) • Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 3 6653.48(184.0-290790) • Brain oedema 4 954425.50-256.60) • • • Dementia Alzheimer's type 3 6453.48(184.0-29079.0) • • Subarachnoid haemorrhage 4 95425.50-256.60) • • • Corrifusional state 14 1602872.339.108.80) • • • • Corrifusional state 14 160609.69-254.0) • • • • • • • Seizure 4 93(142.30-41.89) • • • <td>45-64</td> <td>Amyloid related imaging abnormality-oedema/effusion</td> <td>15</td> <td>228591(107535 - 485922)</td> <td>•</td>	45-64	Amyloid related imaging abnormality-oedema/effusion	15	228591(107535 - 485922)	•
Confusional state3189(654-60.18)Headache33.72(117-11.85)65-74Amyloid related imaging abnormality-oedema/effusion48274338(18120.8-41533.2)Superficial siderosis of central nervous system71728.4(654.80.44557.1)Amyloid related imaging abnormality-nicrohaemorrhages and haemosiderin deposits2816028.8(10054-26542.5)Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits2816028.8(10054-26542.5)Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits3663.48(1846.10-23979.6)Brain oedema4954.4(35.50-256.60)Brain oedema4954.4(35.50-256.60)Dementia Alzheimer's type364.76(2072-202.3)Cerebral haemorrhage40.2852.39-168.80Cerebral haemorrhage41.701(634-45.67)Confusional state141.6609.69-28.41)Disorientation31.322(134-14.80)Memory impairment35.20(148-16.40)Headache125.20(24-9.30)Headache125.20(24-9.30)		Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	н	191839(82497.9 - 446099)	•
Headache33.72(1.17 - 11.85)65.74Amyloid related imaging abnormality-oedema/effusion482.7433.8(18120.8.4.1533.2)Superficial siderosis of central nervous system71.7328.4654.803 - 45857.1)Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits281.6328.8(00454 - 26542.5)Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits281.6328.8(00454 - 26542.5)Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits36653.48(186.10 - 23976)Brain oedema49.544(55.0 - 266.60)Dementia Alzheimer's type364.76(2073 - 202.33)Subarachnoid haemorrhage46.285(23.39 - 168.80)Cerebral haemorrhage41.701(6.34 - 45.67)Disorientation31.342(430 - 41.88)Memoy impairment35.20(168 - 16.40)Headache125.24(24 - 9.3)Gat disturbance43.87(1.44 - 10.38)		Memory impairment	3	19.54(6.14 - 62.19)	-
65-74Amyloid related imaging abnormality-oedema/effusion4827433.8(18120.8-41533.2)ISuperficial sidenosis of central nervous system717728.4(654.03 -45857.1)IAmyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits2816328.8(100454 - 2642.5)IAmyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits2816328.8(100454 - 2642.5)IAmyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits36453.48(186.10 - 23979.6)IBrain oedema495.44(35.50 - 256.60)IIDementia Alzheimer's type36476(073 - 202.33)IICerebral haemorrhage462.85(23.39 - 168.86)IICerebral haemorrhage41701(6.34 - 45.67)IIDisorientation313.42(43 - 41.88)IISeizure49.36(349 - 25.12)IIHeadache125.20(168 - 16.40)IIGait disturbance43.87(1.44 - 10.38)I		Confusional state	3	18.91(5.94 - 60.18)	-
Superficial siderosis of central nervous system 7 17328.4(6548.0) -45857.1) Image: contral nervous system Annyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 28 16328.8(00454 - 26542.5) Image: contral nervous system Annyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 28 16328.8(00454 - 26542.5) Image: contral nervous system Annyloid related imaging abnormalities 3 6633.48(186.10 - 23979.6) Image: contral nervous system Brain oedema 4 95.44(35.50 - 256.60) Image: contral nervous system Image: contral nervous system Dementia Alzheimer's type: 3 64.7(20.73 - 202.33) Image: contral nervous system Image: contral nervous system Subarachnoid haemorrhage 4 0.54(20.37 - 202.33) Image: contral nervous system Image: contral nervous system Confusional state 14 16.00(9.69 - 28.41) Image: contral nervous system		Headache	3	3.72(1.17 - 11.85)	•
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 28 16328.8(100454 - 26542.5) I Amyloid related imaging abnormalities 3 6633.48(186.10 - 23979.6) I Brain oedema 4 95.44(35.50 - 26.60) IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	65-74	Amyloid related imaging abnormality-oedema/effusion	48	27433.8(18120.8 - 41533.2)	•
Annyloid related imaging abnormalities 3 6633.48(186.10 - 23979.6) • Brain oedema 4 95.44(35.50 - 256.60) • • Dementia Alzheimer's type: 3 64.76(2073 - 202.33) • • Subarachnoid haemorrhage 4 62.85(23.39 - 168.86) • • Cerebral haemorrhage 4 62.85(23.39 - 168.86) • • Confusional state 14 16.60(9.69 - 28.41) • • Disorientation 3 13.42(430 - 41.88) • • Memory impairment 3 5.20(1.68 - 16.40) • • Headache 12 5.24(2.94 - 9.34) • • Gait disturbance 4 3.87(1.44 - 10.38) • •		Superficial siderosis of central nervous system	7	17328.4(6548.03 - 45857.1)	•
Brain oedema 4 95.44(35.50-256.60) Dementia Alzheimer's type 3 64.76(20.73-202.33) Subarachnoid haemorrhage 4 62.85(23.39-168.86) Cerebral haemorrhage 4 62.85(23.39-168.86) Confusional state 14 16.60(9.69-28.41) Disorientation 3 13.42(4.30-41.88) Seizure 4 9.36(3.49-25.12) Memory impairment 3 5.20(1.68-16.40) Headache 12 5.24(2.94-9.34) Gait disturbance 4 3.87(1.44-10.88)		Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	28	16328.8(10045.4 - 26542.5)	•
Dementia Alzheimer's type: 3 64.76(20.73 - 202.33)		Amyloid related imaging abnormalities	3	6653.48(1846.10 - 23979.6)	•
Subarachnoid haemorrhage 4 62.85(23.39-168.86) • Cerebral haemorrhage 4 17.01(6.34 - 45.67) • Confusional state 14 16.60(9.69 - 28.41) • Disorientation 3 13.42(4.30 - 41.88) • Memory impairment 3 5.26(1.68 - 16.40) • Headache 12 5.24(2.94 - 9.34) • Gait disturbance 4 3.87(1.44 - 10.38) •		Brain oedema	4	95.44(35.50 - 256.60)	
Cerebral haemorrhage 4 1701(6.34 - 45.67) Confusional state 14 16.60(9.69 - 28.41) Disorientation 3 13.42(4.30 - 41.88) Seizure 4 9.36(3.49 - 25.12) Memory impairment 3 5.26(1.68 - 16.40) Headache 12 5.24(2.94 - 9.34) Gait disturbance 4 3.87(1.44 - 10.38)		Dementia Alzheimer's type	3	64.76(20.73 - 202.33)	
Confusional state 14 1660(969 - 28.41) Disorientation 3 13.42(430 - 41.88) Seizure 4 9.36(3.49 - 25.12) Memory impairment 3 5.26(1.68 - 16.40) Headache 12 5.24(2.94 - 9.34) Gait disturbance 4 3.87(1.44 - 10.38)		Subarachnoid haemorrhage	4	62.85(23.39 - 168.86)	
Disorientation 3 13.42(4.30 - 41.88) Seizure 4 9.36(3.49 - 25.12) Memory impairment 3 5.26(1.68 - 16.40) Headache 12 5.24(2.94 - 9.34) Gait disturbance 4 3.87(1.44 - 10.38)		Cerebral haemorrhage	4	17.01(6.34 - 45.67)	-
Seizure 4 936(3.49-25.12) • Memory impairment 3 526(1.68-16.40) • Headache 12 524(294-9.34) • Gait disturbance 4 3.87(1.44-10.38) •		Confusional state		16.60(9.69 - 28.41)	-
Memory impairment 3 5.26(1.68 - 16.40) II Headache 12 5.24(2.94 - 9.34) II Gait disturbance 4 3.87(1.44 - 10.38) II		Disorientation		13.42(4.30 - 41.88)	•
Headache 12 5.24(2.94 - 9.34) II Gait disturbance 4 3.87(1.44 - 10.38) II					•
Gait disturbance 4 3 87(1.44 - 10.38)					•
					1
		Gait disturbance	4	3.87(1.44 - 10.38)	1 200

FIGURE 6

Age-stratified analysis of adverse events associated with aducanumab: A reporting odds ratio analysis in three age groups. The report of odds ratio (ROR) analysis of adverse events stratified by age groups (45-64, 65-74, and ≥ 75 years) for aducanumab treatment. The forest plot displays preferred terms (PT) on the y-axis and corresponding ROR values with 95% confidence intervals (CI) on the x-axis. ARIA-related events showed the highest reporting odds across all age groups. Other significant adverse events include cognitive disorders, neurological symptoms, and cerebrovascular events, with varying frequencies among different age groups. Abbreviations: ARIA, Amyloid related imaging abnormality-oedema/effusion; ARIA-H, Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits; CI, Confidence interval; COVID-19, Coronavirus disease 2019; PT, Preferred terms; ROR, Reporting odds ratio.



FIGURE 7

Information component analysis heat map of aducanumab-associated adverse events from. Adverse events are listed on the y-axis, while the x-axis displays IC-2SD values for three categories: ALL, Non-Serious, and Serious events. The blue intensity represents the signal strength. Abbreviations: COVID-19, Coronavirus disease 2019; IC, Information component; SD, Standard deviation.

option when accompanied by appropriate patient screening and monitoring protocols. The establishment of clear safety patterns and risk factors through this analysis contributes significantly to the evolving landscape of Alzheimer's disease treatment, providing clinicians with essential data for informed decision-making and patient care optimization. As our understanding of the drug's longterm safety profile continues to evolve, ongoing pharmacovigilance efforts will remain crucial in ensuring optimal therapeutic outcomes for patients with Alzheimer's disease.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by the Committee of First Affiliated Hospital of Guangxi Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants' legal guardians/next of kin because Written informed consent was waived for this study because: 1. This study utilized de-identified data from the publicly accessible FDA Adverse Event Reporting System (FAERS) database 2. No personal identifiable information was collected or accessed during the research process 3. The retrospective analysis of pharmacovigilance data posed no additional risk to patients 4. The study met the criteria for exempt research under 45 CFR 46.104(d)(4) for secondary research use of existing data.

Author contributions

JH: Conceptualization, Formal Analysis, Investigation, Validation, Visualization, Writing-original draft. XL: Supervision, Validation, Visualization, Writing-review and editing. CC: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Software, Supervision, Writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was funded by Guangxi Autonomous Region Higher Education Undergraduate Teaching Reform Project (2024JGA144); Middle-aged and Young Teachers' Basic Ability Promotion Project of Guangxi (2023KY0087, 2023KY0110); Guangxi Education Science 2022 Higher Education Internationalization Special Project (2022ZJY3083); and the Health Commission Self-Funded Scientific Research Projects of Guangxi, China (Z-A20230521, Z-A20230528, Z-C20220835).

Acknowledgments

Data for this investigation were extracted from the FDA Adverse Event Reporting System (FAERS). The analyses and interpretations contained in this study are independent of and do not represent the FDA's official stance. Statistical analyses were thoroughly reviewed by Mr. Shun Dai, Senior Statistical Researcher from Wuhan Tritium Biopharmaceutical Technology Co., Ltd., whose expert guidance ensured the robustness and reliability of the statistical methods employed in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., et al. (2023). Amyloid-related imaging abnormalities in alzheimer disease treated with anti-amyloid- β therapy. *Radiogr. a Rev. Publ. Radiological Soc. N. Am. Inc* 43 43, e230009. doi:10.1148/rg.230009

Ali, R., Gupta, G. D., and Chawla, P. A. (2022). Aducanumab: a new hope in Alzheimer's disease. *Health Sci. Rev.* 4, 100039. doi:10.1016/j.hsr.2022.100039

Alzheimer's Association (2024). Alzheimer's disease facts and figures. ALZHEIMER'S Dement. 20, 3708–3821. doi:10.1002/alz.13809

Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., and Raheem, A. (2024). Unraveling Alzheimer's: the promise of aducanumab, lecanemab, and donanemab. *EGYPT J. NEUROL. PSYCHIATRY Neurosurg.* 60, 72. doi:10.1186/s41983-024-00845-5

Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., et al. (2023). The future of precision medicine in the cure of Alzheimer's disease. *Biomedicines* 11, 335. doi:10.3390/biomedicines11020335

Arias, J. J., Tyler, A. M., Douglas, M. P., and Phillips, K. A. (2021). Private payer coverage policies for ApoE-e4 genetic testing. *Genet. Med.* 23, 614–620. doi:10.1038/s41436-020-01042-4

Generative AI statement

The author(s) declare that Generative AI was used in the creation of this manuscript. To assist with English language editing and polishing using ChatGPT. The authors reviewed and verified all AI-assisted edits to ensure scientific accuracy and appropriate academic expression.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1522058/ full#supplementary-material

SUPPLEMENTARY FIGURE S1

Time-to-onset analysis of adverse events associated with aducanumab: A cumulative distribution analysis. The figure presents a cumulative time-to-onset analysis of adverse events associated with aducanumab treatment. The x-axis shows the time to event in days (0–360), and the y-axis displays the cumulative percentage of events (0–100%). The median time to event and interquartile range (IQR) are indicated. Abbreviations: IQR, Interguartile range.

SUPPLEMENTARY FIGURE S2

Adverse events analysis of aducanumab: Reporting odds ratio analysis of preferred terms. The reporting odds ratio (ROR) analysis of adverse events associated with aducanumab. The x-axis shows ROR values with 95% confidence intervals (CI), and the y-axis lists Preferred terms (PT). The analysis reveals significant signals for ARIA-E, ARIA-H, and other neurological events. Abbreviations: ARIA, Amyloid related imaging abnormality-oedema/effusion; ARIA-E, Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits; CI, Confidence interval; PT, Preferred terms; ROR, Reporting odds ratio.

Bastrup, J., Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., et al. (2021). Anti-a β antibody aducanumab regulates the proteome of senile plaques and closely surrounding tissue in a transgenic mouse model of Alzheimer's disease. *J. ALZHEIMERS Dis.* 79, 249–265. doi:10.3233/JAD-200715

Blasco, D., and Roberts, J. S. (2023). Editorial: implications of emerging uses of genetic testing for Alzheimer's disease. *J. Prev. ALZHEIMER'S Dis.* 10, 359–361. doi:10.14283/jpad.2023.46

Calero, O., García-Albert, L., Rodríguez-Martín, A., Veiga, S., and Calero, M. (2018). A fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient screening and stratification. *Sci. Rep.* 8, 5969. doi:10.1038/ s41598-018-24320-3

Choi, S. A., Jee, H. J., Bormate, K. J., Kim, Y., and Jung, Y.-S. (2023). Sex differences in the preventive effect of cardiovascular and metabolic therapeutics on dementia. *Biomol. Ther.* 31, 583–598. doi:10.4062/biomolther.2023.115

Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., and Weiner, M. (2021). Aducanumab: appropriate use recommendations. *J. Prev. ALZHEIMER'S Dis.* 8, 398–410. doi:10.14283/jpad.2021.41

Cummings, J. L., Osse, A. M. L., and Kinney, J. W. (2023). Alzheimer's disease: novel targets and investigational drugs for disease modification. *DRUGS* 83, 1387–1408. doi:10.1007/s40265-023-01938-w

Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., et al. (2022). Aducanumab use in symptomatic alzheimer disease evidence in focus: a report of the aan guidelines subcommittee. *NEUROLOGY* 98, 619–631. doi:10.1212/WNL. 0000000000200176

Dickson, S. P., Hennessey, S., Nicodemus Johnson, J., Knowlton, N., and Hendrix, S. B. (2023). Avoiding future controversies in the Alzheimer's disease space through understanding the aducanumab data and FDA review. *ALZHEIMER'S Res. Ther.* 15, 98. doi:10.1186/s13195-023-01238-1

Doran, S. J., and Sawyer, R. P. (2024). Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. *Front. Neurosci.* 18, 1326784. doi:10.3389/fnins.2024.1326784

Fang, H., Su, Z., Wang, Y., Miller, A., Liu, Z., Howard, P. C., et al. (2014). Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics. *Clin. Pharmacol. Ther.* 95, 496–498. doi:10. 1038/clpt.2014.17

Galvin, J. E., Cummings, J. L., Benea, M. L., De Moor, C., Allegri, R. F., Atri, A., et al. (2024). Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset. *ALZHEIMER'S Dement.* 20, 4331–4341. doi:10.1002/alz. 13785

Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., and Atri, A. (2023). Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. *Brain* 146, 4414–4424. doi:10.1093/brain/awad188

Heidebrink, J. L., and Paulson, H. L. (2024). Lessons learned from approval of aducanumab for Alzheimer's disease. *Annu. Rev. Med.* 75, 99–111. doi:10.1146/ annurev-med-051022-043645

Knopman, D. S., Jones, D. T., and Greicius, M. D. (2021). Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. *ALZHEIMER'S Dement.* 17, 696–701. doi:10.1002/alz.12213

Liew, T. M. (2020). Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia. *ALZHEIMER'S Res. Ther.* 12, 135. doi:10.1186/s13195-020-00699-y

Marshall, L. J., Bailey, J., Cassotta, M., Herrmann, K., and Pistollato, F. (2023). Poor translatability of biomedical research using animals — a narrative review. *Altern. Lab. Anim.* 51, 102–135. doi:10.1177/02611929231157756

Musiek, E. S., Gomez-Isla, T., and Holtzman, D. M. (2021). Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. *J. Clin. Invest.* 131, e154889. doi:10.1172/JCI154889

Padala, S. P., and Yarns, B. C. (2022). Under-represented populations left out of Alzheimer's disease treatment with aducanumab: commentary on ethics. *J. Alzheimer's Dis. Rep.* 6, 345–348. doi:10.3233/ADR-220023

Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., et al. (2022). Alzheimer's disease: treatment strategies and their limitations. *Int. J. Mol. Sci.* 23, 13954. doi:10.3390/ijms232213954

Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., and Liu, C.-C. (2022). ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. *Mol. Neurodegener*. 17, 72. doi:10.1186/s13024-022-00574-4

Schneider, L. (2020). A resurrection of aducanumab for Alzheimer's disease. *LANCET* NEUROL. 19, 111–112. doi:10.1016/S1474-4422(19)30480-6

Selkoe, D. J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol. Med.* 8, 595–608. doi:10.15252/emmm.201606210

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., et al. (2016). The antibody aducanumab reduces $A\beta$ plaques in Alzheimer's disease. *NATURE* 537, 50–56. doi:10.1038/nature19323

Silva, L., Pacheco, T., Araújo, E., Duarte, R. J., Ribeiro-Vaz, I., and Ferreira-da-Silva, R. (2024). Unveiling the future: precision pharmacovigilance in the era of personalized medicine. *Int. J. Clin. PHARM-NET* 46, 755–760. doi:10.1007/s11096-024-01709-x

Skaria, A. P. (2022). The economic and societal burden of Alzheimer disease: managed care considerations. *Am. J. Manag. Care* 28, S188–S196. doi:10.37765/ ajmc.2022.89236

Tampi, R. R., Forester, B. P., and Agronin, M. (2021). Aducanumab: evidence from clinical trial data and controversies. *DRUGS CONTEXT* 10, 1–9. doi:10.7573/dic.2021-7-3

Tripathi, A., Pandey, V. K., Sharma, G., Sharma, A. R., Taufeeq, A., Jha, A. K., et al. (2024). Genomic insights into dementia: precision medicine and the impact of geneenvironment interaction. *Aging Dis.* 15, 2113–2135. doi:10.14336/AD.2024.0322

van der Flier, W. M., de Vugt, M. E., Smets, E. M. A., Blom, M., and Teunissen, C. E. (2023). Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia. *Nat. Aging* 3, 494–505. doi:10.1038/s43587-023-00404-2

Vaz, M., Silva, V., Monteiro, C., and Silvestre, S. (2022). Role of aducanumab in the treatment of Alzheimer's disease: challenges and opportunities. *Clin. Interv. AGING* 17, 797–810. doi:10.2147/CIA.S325026

Wang, Y., Zhao, B., Yang, H., and Wan, Z. (2024). A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil. *ANDROLOGY* 12, 785–792. doi:10.1111/andr.13533

Wu, T., Lin, D., Cheng, Y., Jiang, S., Riaz, M. W., Fu, N., et al. (2022). Amyloid cascade hypothesis for the treatment of Alzheimer's disease: progress and challenges. *AGING Dis.* 13, 1745–1758. doi:10.14336/AD.2022.0412